Literature DB >> 2369684

Myasthenia gravis after allogeneic bone marrow transplantation: report of a new case and pathogenetic considerations.

J M Grau1, J Casademont, R Monforte, P Marín, A Grañena, C Rozman, A Urbano-Márquez.   

Abstract

A 21-year-old caucasian man with T acute lymphoblastic leukemia underwent a bone marrow transplantation (BMT) and developed classic myasthenia gravis (MG) 46 months later. The association of almost all published cases with HLA B35 is discussed, as are the clinical aspects suggesting that BMT survivors are at risk for developing MG as part of the spectrum of chronic graft-versus-host disease.

Entities:  

Mesh:

Year:  1990        PMID: 2369684

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  5 in total

1.  Haemopoietic stem and progenitor cells in the treatment of severe autoimmune diseases.

Authors:  A Tyndall; A Gratwohl
Journal:  Ann Rheum Dis       Date:  1996-03       Impact factor: 19.103

2.  Autoimmune polyendocrine failure--type 1 (insulin-dependent) diabetes mellitus and hypothyroidism--after allogeneic bone marrow transplantation in a patient with lymphoblastic leukaemia.

Authors:  B Vialettes; D Maraninchi; M P San Marco; F Birg; A M Stoppa; C Mattei-Zevaco; C Thivolet; L Hermitte; P Vague; P Mercier
Journal:  Diabetologia       Date:  1993-06       Impact factor: 10.122

Review 3.  Thymus, thymoma and myasthenia gravis.

Authors:  Yoshitaka Fujii
Journal:  Surg Today       Date:  2012-09-05       Impact factor: 2.549

4.  Complete neurologic and cognitive recovery after plasmapheresis in a patient with chronic inflammatory demyelinating polyneuropathy after allogeneic hematopoietic stem cell transplantation.

Authors:  Ursula Vogl; Gerda Leitner; Assunta Dal-Bianco; Marija Bojic; Margit Mitterbauer; Werner Rabitsch; Peter Kalhs; Axel Schulenburg
Journal:  Wien Klin Wochenschr       Date:  2016-02-26       Impact factor: 1.704

Review 5.  Stem Cell Therapy in Neuroimmunological Diseases and Its Potential Neuroimmunological Complications.

Authors:  Franz Felix Konen; Philipp Schwenkenbecher; Konstantin Fritz Jendretzky; Stefan Gingele; Lea Grote-Levi; Nora Möhn; Kurt-Wolfram Sühs; Britta Eiz-Vesper; Britta Maecker-Kolhoff; Corinna Trebst; Thomas Skripuletz; Martin W Hümmert
Journal:  Cells       Date:  2022-07-11       Impact factor: 7.666

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.